WALTHAM, Mass.--(BUSINESS WIRE)--Mar. 12, 2018--
OvaScienceSM, Inc. (NASDAQ: OVAS), a company focused on the
discovery, development and commercialization of new treatment options
for women and families struggling with infertility, today announced the
grant of an inducement award to its newly appointed Chief Scientific
Officer, James W. Lillie, Ph.D. The award was approved by OvaScience’s
Board of Directors on March 6, 2018 as an inducement material to Dr.
Lillie entering into employment with the Company, as permitted under
Nasdaq Listing Rule 5635(c)(4). The inducement grant to Dr. Lillie
consisted of an option to purchase up to 357,057 shares of common stock.
The stock options are exercisable at a price of $1.02 per share, equal
to the closing price per share of OvaScience’s common stock as reported
by Nasdaq on March 6, 2018. The stock options vest over four years, with
25% of such options vesting on January 16, 2019 and 6.25% of such
options vesting at the end of each subsequent quarter thereafter,
subject to Dr. Lillie’s continued service with the Company through the
applicable vesting dates.
OvaScienceSM, Inc. (NASDAQ:OVAS)
is a fertility company focused on the discovery, development and
commercialization of new treatment options for women and families
struggling with infertility. Each OvaScience treatment is based on the
Company’s proprietary technology platform that leverages the
breakthrough discovery of egg precursor (EggPC℠) cells – immature egg
cells found within the outer ovarian cortex. OvaScience is developing
the OvaPrime℠ treatment, which could increase a woman’s egg reserve and
the OvaTure℠ treatment, a potential in vitro fertilization (IVF)
treatment that could help a woman produce new fertilizable eggs without
hormone injections. OvaScience’s AUGMENT℠ treatment is a fertility
option designed to improve IVF success rates. OvaScience treatments are
not available in the United States. For more information, visit www.ovascience.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180312005811/en/
Source: OvaScience, Inc.
Media and Investor Contact: